4.7 Article

KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas

期刊

INTERNATIONAL JOURNAL OF CANCER
卷 123, 期 4, 页码 793-800

出版社

WILEY-LISS
DOI: 10.1002/ijc.23576

关键词

stem cell factor receptor; KIT; astrocyte

类别

向作者/读者索取更多资源

Activating gene mutations, gene amplifications and overexpressed proteins may be useful as targets for novel therapies. Alterations at chromosome locus 4q12 are associated with gliomas and the region harbors the receptor tyrosine kinase gene KIT, which is frequently amplified in gliomas, and also overexpressed in a subset of gliomas. KIT and its ligand stem cell factor are widely expressed in embryonic and adult mouse brain, and they play a role in many signal transduction pathways involved in cellular proliferation, differentiation and cancer cell metastasis. However, the function of KIT in gliomagenesis or disease progression remains unresolved as well as its role in neural and brain tumor development. In this study, we utilized lentivirus-mediated gene transfer to deliver the KIT gene into mouse astrocytes. The growth properties of KIT overexpressing cells were analyzed using several in vitro functional assays. The effect of receptor tyrosine kinase inhibitor imatinib on astrocyte growth was also investigated. Our results indicate that overexpression of KIT in mouse astrocytes promotes cell proliferation, and the increased proliferation is partly inhibited by imatinib treatment. Furthermore, KIT overexpression induces phenotypic changes in the cells suggesting that KIT may play a role in astrocyte growth regulation. (c) 2008 Wiley-Liss, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Food Science & Technology

Screening for six genetically modified soybean lines by an event-specific multiplex PCR method: Collaborative trial validation of a novel approach for GMO detection

Lutz Grohmann, Anke Belter, Brigitte Speck, Ottmar Goerlich, Patrick Guertler, Alexandre Angers-Loustau, Alex Patak

JOURNAL OF CONSUMER PROTECTION AND FOOD SAFETY (2017)

Article Chemistry, Applied

Molecular characterization of an unauthorized genetically modified Bacillus subtilis production strain identified in a vitamin B2 feed additive

Valentina Paracchini, Mauro Petrillo, Ralf Reiting, Alexandre Angers-Loustau, Daniela Wahler, Andrea Stolz, Birgit Schoenig, Anastasia Matthies, Joachim Bendiek, Dominik M. Meinel, Sven Pecoraro, Ulrich Busch, Alex Patak, Joachim Kreysa, Lutz Grohmann

FOOD CHEMISTRY (2017)

Article Food Science & Technology

Novel nuclear barcode regions for the identification of flatfish species

Valentina Paracchini, Mauro Petrillo, Antoon Lievens, Antonio Puertas Gallardo, Jann Thorsten Martinsohn, Johann Hofherr, Alain Maquet, Ana Paula Barbosa Silva, Dafni Maria Kagkli, Maddalena Querci, Alex Patak, Alexandre Angers-Loustau

FOOD CONTROL (2017)

Article Food Science & Technology

Identification of single target taxon-specific reference assays for the most commonly genetically transformed crops using digital droplet PCR

Sara Jacchia, Dafni-Maria Kagkli, Antoon Lievens, Alexandre Angers-Loustau, Christian Savini, Hendrik Emons, Marco Mazzara

FOOD CONTROL (2018)

Article Biotechnology & Applied Microbiology

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses

Erkko Ylosmaki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylosmaki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala, Vincenzo Cerullo

MOLECULAR THERAPY (2018)

Article Cell Biology

Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint

Ting Wei, Saman M. Najmi, Hester Liu, Karita Peltonen, Alena Kucerova, David A. Schneider, Marikki Laiho

CELL REPORTS (2018)

Article Oncology

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

S. Feola, C. Capasso, M. Fusciello, B. Martins, S. Tahtinen, M. Medeot, S. Carpi, F. Frascaro, E. Ylosmaki, K. Peltonen, L. Pastore, V. Cerullo

ONCOIMMUNOLOGY (2018)

Article Multidisciplinary Sciences

Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy

Leena Ylosmaki, Beatrice Polini, Sara Carpi, Beatriz Martins, Elena Smertina, Sara Feola, Manlio Fusciello, Karita Peltonen, Paola Nieri, Erkko Ylosmaki, Vincenzo Cerullo

PLOS ONE (2019)

Article Oncology

Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy

Siri Tahtinen, Sara Feola, Cristian Capasso, Netta Laustio, Christianne Groeneveldt, Erkko O. Ylosmaki, Leena Ylosmaki, Beatriz Martins, Manlio Fusciello, Marta Medeot, Maria Tagliamonte, Jacopo Chiaro, Firas Hamdan, Karita Peltonen, Tuuli Ranki, Luigi Buonaguro, Vincenzo Cerullo

CANCER RESEARCH (2020)

Article Multidisciplinary Sciences

Artificially cloaked viral nanovaccine for cancer immunotherapy

Manlio Fusciello, Flavia Fontana, Siri Tahtinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Ylosmaki, Erkko Ylosmaki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, Helder A. Santos, Vincenzo Cerullo

NATURE COMMUNICATIONS (2019)

Article Oncology

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma

Jacopo Chiaro, Henna H. E. Kasanen, Thomas Whalley, Cristian Capasso, Mikaela Gronholm, Sara Feola, Karita Peltonen, Firas Hamdan, Micaela Hernberg, Siru Makela, Hanna Karhapaa, Paul E. Brown, Beatriz Martins, Manlio Fusciello, Erkko O. Ylosmaki, Dario Greco, Anna S. Kreutzman, Satu Mustjoki, Barbara Szomolay, Vincenzo Cerullo

Summary: This study examined the impact of molecular mimicry on cancer immunotherapy, demonstrating that preexisting antiviral immunity may enhance the effectiveness of cancer immunotherapy through molecular mimicry. It was also observed that high levels of CMV-specific antibodies were associated with prolonged progression-free survival in melanoma patients undergoing anti-PD1 treatment, suggesting a potential link between immune responses to viruses and cancer. Additionally, T-cell receptor sequencing revealed expansion of specific CD8(+) T-cell clones indicating cross-reactivity between tumor and viral peptides.

CANCER IMMUNOLOGY RESEARCH (2021)

Article Oncology

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy

Karita Peltonen, Sara Feola, Husen M. Umer, Jacopo Chiaro, Georgios Mermelekas, Erkko Ylosmaki, Sari Pesonen, Rui M. M. Branca, Janne Lehtio, Vincenzo Cerullo

Summary: This study explores a novel oncolytic adenovirus vaccine platform as immunotherapy in resistant tumors, customized for improved tumor targeting based on experimentally discovered tumor antigens; the pipeline may be applied for designing personalized therapeutic cancer vaccines, which is crucial for broader design and utility of therapeutic cancer vaccines. The study integrates immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy, showing promising control of established tumors using a flexible and specific tumor targeting oncolytic adenovirus platform.

CANCERS (2021)

Article Chemistry, Multidisciplinary

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification

Sara Feola, Markus Haapala, Karita Peltonen, Cristian Capasso, Beatriz Martins, Gabriella Antignani, Antonio Federico, Vilja Pietiainen, Jacopo Chiaro, Michaela Feodoroff, Salvatore Russo, Antti Rannikko, Manlio Fusciello, Satu Koskela, Jukka Partanen, Firas Hamdan, Sari M. Tahka, Erkko Ylosmaki, Dario Greco, Mikaela Gronholm, Tuija Kekarainen, Masoumeh Eshaghi, Olga L. Gurvich, Seppo Yla-Herttuala, Rui M. M. Branca, Janne Lehtio, Tiina M. Sikanen, Vincenzo Cerullo

Summary: This study successfully identified and characterized tumor-specific ligands using a microfluidic-based chip, highlighting the potential for personalized cancer therapeutic vaccine design. The developed technology showed improved efficiency in isolating peptides and has the capability for high-throughput analysis with potential clinical applications.

ACS NANO (2021)

Article Medicine, Research & Experimental

Single-cell characterization of anti-LAG-3 and anti- PD-1 combination treatment in patients with melanoma

Jani Huuhtanen, Henna Kasanen, Katriina Peltola, Tapio Lonnberg, Virpi Glumoff, Oscar Bruck, Olli Dufva, Karita Peltonen, Johanna Vikkula, Emmi Jokinen, Mette Ilander, Moon Hee Lee, Siru Makela, Marta Nyakas, Bin Li, Micaela Hernberg, Petri Bono, Harri Lahdesmaki, Anna Kreutzman, Satu Mustjoki

Summary: Relatlimab plus nivolumab (anti-LAG-3+anti-PD-1) has been approved by the FDA for first-line therapy in stage III/IV melanoma, but its impact on the immune system is not well understood. This study evaluated blood samples from 40 metastatic melanoma patients treated with anti-LAG-3+anti-PD-1 and found significant changes in NK cells, Tregs, and CD8+ T cells during the treatment. The study also observed differences in the transcriptome profile and TCR clonality between responders and non-responders.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Meeting Abstract Biotechnology & Applied Microbiology

PeptiCHIP: A Novel Microfluidic-Based Chip Platform for Tumour Antigen Landscape Identification

Sara Feola, Markus Haapala, Karita Peltonen, Cristian Capasso, Beatriz Martins, Gabriella Antignani, Antonio Federico, Vilja Pietiainen, Jacopo Chiaro, Michaela Feodoroff, Antti Ranniko, Manlio Fusciello, Satu Koskela, Jukka Partanen, Firas Hamdan, Sari Tahka, Erkko Ylosmaki, Dario Greco, Mikaela Gronholm, Tuija Kekarainen, Masoumeh Eshaghi, Olga L. Gurvich, Seppo Yla-Herttuala, Rui M. M. Branca, Janne Lehtio, Tiina Sikanen, Vincenzo Cerullo

MOLECULAR THERAPY (2021)

Article Oncology

Anal cancer screening results from 18-to-34-year-old men who have sex with men living with HIV

Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa

Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.

INTERNATIONAL JOURNAL OF CANCER (2024)